- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01806714
Text Reminders to Immunize in a Managed Care Organization (TRIO)
The purpose of the study is to evaluate the effectiveness of a managed care-based HPV vaccination reminder/recall system using a randomized controlled trial (RCT) across diverse practices and patient populations. The trial will measure the effectiveness of text messaging reminder/recall on (a) improving initiation and (b) completion rate of the HPV vaccine series; (c) decreasing the time between vaccine doses; and (d) improving rates of preventive visits for adolescents
The hypotheses are that text-messaged reminders to parents of adolescents will result in improved rates of HPV vaccine series initiation, HPV vaccine series completion, will decrease the intervals between vaccine doses and will improve rates of preventive care among adolescents. Parents receiving specific text-messaged reminders about services (i.e. HPV vaccination, well child care visits) for which their adolescent is due will be compared to a control group of parents receiving general health tips through text messages.
Study Overview
Status
Conditions
Detailed Description
The study setting is western New York State and the Southern Tier of New York State (15 counties total). Investigators will work with the Monroe Plan for Medical Care, an IPA-model managed care organization (MCO) that serves Medicaid managed care and SCHIP enrollees. The MCO will conduct regular reviews of insurance claims data and the New York State Immunization Information System of adolescents ages 11-<16 years. Parents (all over 18 years of age) of adolescents will receive the texted messages on their phones.
There are no enrollment restrictions based upon race or ethnic origin. The inclusion criteria are that the adolescents are a) enrolled in Medicaid or SCHIP through the Monroe Plan, b) have been enrolled greater than 6 months with the Monroe Plan (in order to have sufficient claims data to determine whether they are due for a well child care visit or recommended immunizations), c) the Monroe Plan has received their consent to send preventive care text messages, d) their child attend a primary care practice that has agreed to participate and d) they are between the ages of 11-<16 years at the start of the study.
The key independent measure is group allocation (intervention vs. control); an intention-to-treat strategy will be used to assess the effectiveness of text messaging reminders. Key outcome measures will be: 1) receipt of 0, 1, 2 or 3 doses of HPV vaccine 2) interval (in days) between doses and 3) having a preventive visit in the 6 month period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 11-<18 years
- Member of MCO for >6 months
- Opted in to receive texted reminders from MCO
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Text-based reminder for HPV vaccine/WCC
Parents of adolescents will receive text-based reminders if their adolescent is due for HPV vaccine (dose 1, 2 or 3) or well child care visit
|
Patients due for a well visit or HPV vaccine received a text reminder
|
|
Active Comparator: Control arm
Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
|
Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Receiving HPV Vaccination (Dose 1)
Time Frame: 9 months
|
Participants who received HPV vaccine dose 1 Kaplan-Meier failure function
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Receiving HPV Vaccination (Dose 2)
Time Frame: 9 months
|
Participants who received HPV vaccine dose 2 at end of study period Kaplan-Meier failure function
|
9 months
|
|
Percentage of Participants Receiving HPV Vaccination (Dose 3)
Time Frame: 9 months
|
Participants who received HPV vaccine dose 3 at end of study period Kaplan-Meier failure function
|
9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cynthia M Rand, MD, MPH, University of Rochester
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 056103-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papilloma Virus
-
Atila Biosystems Inc.Basic Health InternationalRecruitingHuman Papilloma VirusUnited States, El Salvador, Honduras
-
Regenstrief Institute, Inc.Merck Sharp & Dohme LLCCompletedCervical Cancer | Human Papilloma Virus Infection Type 11 | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Human Papilloma Virus Infection Type 6United States
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Daré Bioscience, Inc.Advanced Research Projects Agency for Health (ARPA-H)Not yet recruitingHuman Papilloma Virus (HPV) | High-risk Human Papillomavirus InfectionUnited States
-
Universiteit AntwerpenUniversitaire Ziekenhuizen KU Leuven; University Hospital, Ghent; University...RecruitingHuman Papilloma Virus Infection Type 16Belgium
-
Benha UniversityCompletedCutaneous Warts | Human Papilloma Virus (HPV)Egypt
-
Çankırı Karatekin UniversityNot yet recruitingHearing Disability | Human Papilloma Virus (HPV)
-
Fondazione Policlinico Universitario Agostino Gemelli...Lo.Li.Pharma s.r.lNot yet recruitingHPV - Anogenital Human Papilloma Virus Infection | Infertilities
-
General University Hospital, PragueNot yet recruitingCervical Cancer Screening | Human Papilloma Virus (HPV)
-
Xiamen Innovax Biotech Co., LtdZhejiang Provincial Center for Disease Control and PreventionActive, not recruitingHuman Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Hepatitis E Virus InfectionChina
Clinical Trials on Text-based reminder for recommended HPV vaccine or WCC
-
Memorial Sloan Kettering Cancer CenterHackensack Meridian HealthActive, not recruiting
-
Temple UniversityNational Institute of Mental Health (NIMH)Not yet recruitingStress | HIV Treatment Cascade | HIV Care Loss to Followup
-
University Health Network, TorontoCanadian Institutes of Health Research (CIHR); Samuel Lunenfeld Research Institute... and other collaboratorsActive, not recruitingVaccine Response | COVID-19 Virus InfectionCanada
-
Beijing Tiantan HospitalNot yet recruitingRespiratory Failure | Respiratory Infection Virus